ESMO 2023

Highlights from the ASCO congress 2023 for Ribociclib

Ribociclib

 

Resources related to Ribociclib 

Frame 427318444
RIGHT Choice phase II study update
RIGHT Choice phase II study update

QoL analysis from the RIGHT Choice study of 1L RIB+ET vs combination CT in aggressive HR+/HER2− aBC.

See more details
Frame 427318444
RIGHT Choice phase II study update
RIGHT Choice phase II study update

1L RIB+ET vs combination CT in aggressive HR+/HER2− aBC: a subgroup analysis of patients with or without visceral crisis

See more details
Frame 427318444
Real-world data from the RIBANNA study (Germany) - 5th interim analysis
Real-world data from the RIBANNA study (Germany) - 5th interim analysis

Treatment of elderly patients (>75 years) with first-line ribociclib + endocrine therapy or endocrine monotherapy in clinical routine

See more details
Rectangle 4765
Real-world data from the RIBANNA study (Germany)
Real-world data from the RIBANNA study (Germany)

Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant in subgroups of special interest

See more details
Frame 427318444
Real-world data from the RIBANNA study (Germany)
Real-world data from the RIBANNA study (Germany)

Therapy management and safety of first-line ribociclib + aromatase inhibitor/fulvestrant in clinical routine

See more details
Small

Ribociclib highlight from an artificial intelligence perspective

 

It only takes you 3 minutes to get the latest news about the Right Choice trial! 
Whilst striving for innovation we are piloting a tool using artificial intelligence to deliver a podcast. 

Listen

 

Abbreviations: 
QoL: quality of life; 1L: first-line; RIB: ribociclib; ET: endocrine therapy; CT: chemotherapy; HR+ : hormone receptor positive; HER2− : human epidermal growth factor receptor 2 negative; aBC: advanced breast cancer

Source URL: https://www.pro.novartis.com/ch-de/kongresse-und-events/onkologie/esmo-2023